Advertisement

Antithrombotic Drugs for the Treatment of Heparin-Induced Thrombocytopenia

  • Walter P. Jeske
  • Jeanine M. Walenga
Part of the Methods In Molecular Medicine™ book series (MIMM, volume 93)

Abstract

Heparin remains the anticoagulant of choice in the therapy of thromboembolic events. Heparin is effective in the prevention and treatment of venous thromboembolism (VTE), as a surgical anticoagulant, and in interventional cardiology (1). Heparin is also used in the treatment of unstable angina and acute myocardial infarction (AMI), and in some patients with disseminated intravascular coagulation. Although the clinical effects of heparin are meritorious, side effects do occur. Bleeding is the primary undesirable effect of heparin. Heparin-induced thrombocytopenia (HIT), the most frequent of drug-induced allergies, necessitates the use of alternative agents to treat or prevent thrombus formation.

Keywords

International Normalize Ratio Activate Clotting Time Percutaneous Coronary Interventional Direct Thrombin Inhibitor Heparin Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., et al. (2001) Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 119, 64S–94S.PubMedCrossRefGoogle Scholar
  2. 2.
    Lewis, B. E., Walenga, J. M., and Wallis, D. E. (1997) Anticoagulation with Novastan® (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin. Thromb. Hemost. 23(2), 197.PubMedCrossRefGoogle Scholar
  3. 3.
    Messmore, H. L., Upadhyay, G., Farid, S., Parachuri, R., Wehrmacher, W., and Godwin, J. (1993) Heparin-induced thrombocytopenia and thrombosis in cardiovascular surgery, in New Anticoagulants for the Cardiovascular Patient (Pifarré, R., ed.), Philadelphia, Hanley & Belfus, Inc., p. 83.Google Scholar
  4. 4.
    Walenga, J. M., Lewis, B. E., Hoppensteadt, D. A., Fareed, J., and Bakhos, M. (1997) Management of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Clin. Appl. Thromb. Hemost. 3(Suppl. 1), S53–S63.CrossRefGoogle Scholar
  5. 5.
    Warkentin, T. E. and Kelton, J. G (2001) Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344(17), 1286–1292.PubMedCrossRefGoogle Scholar
  6. 6.
    Warkentin, T. E. and Kelton, J. G. (2001) Delayed onset of heparin-induced thrombocytopenia. Ann. Intern. Med. 135(7), 502–506.PubMedGoogle Scholar
  7. 7.
    Walenga, J. M., Jeske, W. P., Wood, J. J., Ahmad, S., Lewis, B. E., and Bakhos, M. (1999) Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin. Hematol. 36(Suppl. 1), 22–28.PubMedGoogle Scholar
  8. 8.
    Walenga, J. M., Jeske, W. P., Fasanella, A. R., Wood, J. J., Ahmad, S., and Bakhos, M. (1999) Laboratory diagnosis of heparin-induced thrombocytopenia. Clin. Appl. Thromb. Hemost. 5(Suppl. 1), S21–S27.PubMedCrossRefGoogle Scholar
  9. 9.
    Warkentin, T. E., Hayward, C. P., Boshkov, C. K., et al. (1994) Sera from patients with heparin-induced thrombocytopenia generate platelet derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin induced thrombocytopenia. Blood 84, 3691.PubMedGoogle Scholar
  10. 10.
    Warkentin, T. E. and Kelton, J. G. (1996) A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101, 502–507. The authors document the high occurrence of venous thrombosis in patients with HIT and the high 30-d risk of developing thrombosis in patients initially recognized with isolated thrombocytopenia.PubMedCrossRefGoogle Scholar
  11. 11.
    Greinacher, A., Eckhardt, T., Mussman, J., et al. (1993) Pregnancy complicated by heparin associated thrombocytopenia management by a prospective in vitro selected heparinoid (ORG 10172). Thromb. Res. 71, 123.PubMedCrossRefGoogle Scholar
  12. 12.
    Stewart, M. W., Etches, W. S., Boshkov, L. K., et al. (1995) Heparin-induced thrombocytopenia: an improved method of detection based on lumiaggregometry. Br. J. Haematol. 91, 173.PubMedCrossRefGoogle Scholar
  13. 13.
    Wallis, D. E., Workman, D. L., Lewis, B. E., Steen, L., Pifarré, R., and Moran, J. F. (1999) Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am. J. Med. 106(6), 629–635. Retrospective study of 113 patients with HIT demonstrating that early cessation of heparin did not reduce the morbidity associated with HIT.PubMedCrossRefGoogle Scholar
  14. 14.
    Moberg, P., Geary, V., and Sheikh, M. (1990) Heparin-induced thrombocytopenia: a possible complication of heparin-coated pulmonary artery catheters. J. Cardiothorac. Anesth. 4, 266.CrossRefGoogle Scholar
  15. 15.
    Weismann, R. E. and Tobin, R. W. (1958) Arterial embolism occurring with systemic heparin therapy. AMA Arch. Surg. 76, 219.PubMedCrossRefGoogle Scholar
  16. 16.
    Amiral, J., Bridey, F., Dreyfus, M., et al. (1992) Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemostasis 68(1), 95.Google Scholar
  17. 17.
    Aster, R. H. (1995) Heparin-induced thrombocytopenia and thrombosis. N. Engl. J. Med. 332, 1374.PubMedCrossRefGoogle Scholar
  18. 18.
    Brandt, J. T., Isenhart, C. E., Osborne, J. M., et al. (1995) On the role of platelet Fc(RIIA phenotype in heparin induced thrombocytopenia. Thromb. Haemostasis 74, 1564.Google Scholar
  19. 19.
    Cines, D. B., Tomaski, A., and Tannenbaum, S. (1987) Immune endothelial-cell injury in heparin associated thrombocytopenia. N. Engl. J. Med. 316, 581.PubMedCrossRefGoogle Scholar
  20. 20.
    Greinacher, A., Michels, I., Liebenhoff, U., et al. (1993) Heparin-associated thrombocytopenia: Immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br. J. Haematol. 84, 711.PubMedCrossRefGoogle Scholar
  21. 21.
    Greinacher, A., Pötzsch, B., Amiral, J., et al. (1994) Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multi-molecular PF-4 heparin complex as the major antigen. Thromb. Haemostasis 71, 247.Google Scholar
  22. 22.
    Kelton, J. G., Smith, J. W., Warkentin, T. E., et al. (1994) Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83, 3232.PubMedGoogle Scholar
  23. 23.
    Visentin, G. P., Ford, S. E., Scott, J. P., et al. (1995) Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J. Clin. Invest. 93, 81.CrossRefGoogle Scholar
  24. 24.
    Jeske, W. P., Walenga, J. M., Szatkowski, E., Ero, M., Herbert, J. M., Haas, S., et al. (1997) Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb. Res. 88, 271–281.PubMedCrossRefGoogle Scholar
  25. 25.
    Walenga, J. M., Michal, K., Hoppensteadt, D., Wood, J. J., Bick, R. L., and Robinson, J. A. (1999) Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin. Appl. Thromb. Hemost. 5(Suppl. 1), S76–S84.PubMedCrossRefGoogle Scholar
  26. 26.
    Herbert, J. M., Savi, P., Jeske, W. P., and Walenga, J. M. (1998) Effect of SR121566A, a potent GPIIb/IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb. Haemostasis 80, 326–331.Google Scholar
  27. 27.
    Chong, B. H. (1995) Heparin-induced thrombocytopenia (Review). Br. J. Haematol. 89, 431–439.PubMedCrossRefGoogle Scholar
  28. 28.
    Walenga, J. M., Koza, M. J., Lewis, B. E., and Pifarré, R. (1996) Relative heparin induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin. Appl. Thromb. Hemost. 2(Suppl. 1), S21.Google Scholar
  29. 29.
    Newman, P. M. and Chong, B. H. (2000) Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 96, 182–187.PubMedGoogle Scholar
  30. 30.
    Pouplard, C., Lochmann, S., Renard, B., Herault, O., Colombat, P., Amiral, J., and Gruel, Y. (2001) Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97(10), 3300–3302.PubMedCrossRefGoogle Scholar
  31. 31.
    Hughes, M., Hayward, C. P. M., Warkentin, T E., Horsewood, P., Chorneyko, K. A., and Keltonm, J. G. (2000) Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 96, 188–194.PubMedGoogle Scholar
  32. 32.
    Jeske, W. P., Schlenker, R., Bakhos, M., and Walenga, J. M. (2000) Are leukocytes important for platelet activation in heparin-induced thrombocytopenia? Ann. Hematol. 79(Suppl. I), A46.Google Scholar
  33. 33.
    Jeske, W. P., Vasaiwala, S., Schlenker, R., Wallis, E., and Walenga, J. M. (2000) Leukocyte activation in heparin-induced thrombocytopenia. Blood 96(11), 29b.Google Scholar
  34. 34.
    Blank, M., Shoenfeld, Y., Tavor, S., Praprotnik, S., Boffa, M. C., Weksler, B. B., et al. (2002) Anti-PF4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int. Immunol. 14(2), 121–129.PubMedCrossRefGoogle Scholar
  35. 35.
    Baugh, M. J., Prechel, M., Hoppensteadt, D., Wallis, E. R., Bick, R. L., and Walenga, J. M. (2000) The role of CD40-ligand and anti-annexin V antibodies in the pathophysiology of the APS and HIT. Blood 96(11), 272a.Google Scholar
  36. 36.
    Ahmad, S., Walenga, J. M., Jeske, W. P., Cella, G., and Fareed, J. (1999) Functional heterogeneity of anti-heparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Clin. Appl. Thromb. Hemost. 5(Suppl. 1), S32–S37.PubMedCrossRefGoogle Scholar
  37. 37.
    Ahmad, S., Walenga, J. M., Jeske, W. P., Hoppensteadt, D. A., Khan, E., Cella, G., et al. (1999) Lack of thrombocytopenic responses after low molecular weight heparin usage is due to the generation of non-functional anti-heparin-PF4 antibodies. Blood 94(10), 624a.Google Scholar
  38. 38.
    Mattioli, A. V., Bonetti, L., Sternieri, S., and Mattioli, G. (2000) Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital. Heart. J. 1(1), 39–42. Study shows an increase in thrombotic events at 1 yr follow-up in patients with anti-heparin/PF4 antibodies compared to those without antibodies, despite no evidence of thrombocytopenia.PubMedGoogle Scholar
  39. 39.
    Amiral, J., Pouplard, C., Vissac, A. M., Walenga, J. M., Jeske, W., and Gruel, Y. (2000) Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: Biological characteristics and effects on platelet activation. Br. J. Haematol. 109(2), 336–341.PubMedCrossRefGoogle Scholar
  40. 40.
    Pouplard, C. A., Amiral, J., Vissac, A. M., Walenga, J. M., Jeske, W. P., and Gruel, Y. J. (1999) Affinity purification of different heparin-dependent antibodies to PF4 developed in HIT. Biological characteristics and effects on platelet activation. Blood 94(10), 16a.Google Scholar
  41. 41.
    Carlsson, L. E., Santoso, S., Baurichter, G., Kroll, H., Papenberg, S., Eichler, P., et al. (1998) Heparin-induced thrombocytopenia: new insights into the impact of the Fc(RIIa-R-H131 polymorphism. Blood 92(5), 1526–1531.Google Scholar
  42. 42.
    Kappa, J. R., Fisher, C. A., Berkowitz, H. D., Cottrell, E. D., and Addonizio, V. P. (1987) Heparin-induced platelet activation in sixteen surgical patients: Diagnosis and management. J. Thorac. Cardiovasc. Surg. 5, 101.Google Scholar
  43. 43.
    Warkentin, T. E., Levine, M. N., Hirsh, J., et al. (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332, 1330.PubMedCrossRefGoogle Scholar
  44. 44.
    Ahmad, S., Walenga, J. M., Jeske, W. P., Hoppensteadt, D. A., and Bakhos, M. (2001) Molecular weight and charge dependence of heparin on the pathogenic responses of anti-heparin platelet factor 4 antibodies. Thromb. Haemostasis (July Suppl.), CD-ROM, P2729.Google Scholar
  45. 45.
    Greinacher, A., Feigl, M., and Mueller-Eckhardt, C. (1994) Cross-reactivity studies between sera of patients with heparin associated thrombocytopenia and a new low molecular weight heparin, reviparin. Thromb. Haemostasis 72(4), 644.Google Scholar
  46. 46.
    Altés, A., Rodrigo, M., Gari, M., et al. (1995) Heparin-induced thrombocytopenia and heart operation: management with tedelparin. Ann. Thorac. Surg. 59, 508.PubMedCrossRefGoogle Scholar
  47. 47.
    Leroy, J., LeClerc, M. H., Delahousse, B., et al. (1985) Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin. Thromb. Hemost. 11(3), 326.PubMedCrossRefGoogle Scholar
  48. 48.
    Robitaille, D., Leclerc, J. R., Laberge, R., et al. (1992) Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J. Thome. Cardiovasc. Surg. 103(3), 597.Google Scholar
  49. 49.
    Roussi, J. H., Houbouyan, L. L., and Goguel, A. F. (1984) Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet (May 26), 1183.Google Scholar
  50. 50.
    Eichinger, S., Kyrle, R. A., Brenner, B., et al. (1991) Thrombocytopenia associated with low-molecular-weight heparin. Lancet 337, 1425.PubMedCrossRefGoogle Scholar
  51. 51.
    Gouault-Heilmann, M., Payen, D., Contant, G., et al. (1985) Thrombocytopenia related to synthetic heparin analogue therapy. Thromb. Haemostasis 54(2), 557.Google Scholar
  52. 52.
    Wallis, D. E., Quintos, R., Whermacher, W., and Messmore, H. (1999) Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest 116, 1333–1338.PubMedCrossRefGoogle Scholar
  53. 53.
    Walenga, J. M., Fasanella, A. R., Iqbal, O., Hoppensteadt, D. A., Ahmad, S., Wallis, D. E., et al. (1999) Coagulation laboratory testing in patients treated with argatroban. Semin. Thromb. Hemost. 25(Suppl. 1), 61–66.PubMedGoogle Scholar
  54. 54.
    Sheth, S. B., DiCicco, R. A., Hursting, M. J., Montague, T., and Jorkasky, D. K. (2001) Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb. Haemostasis 85, 435–440.Google Scholar
  55. 55.
    Hursting, M. J., Zehnder, J. L., Joffrion, J. L., Becker, J. C., Knappenberger, G. D., and Schwarz, R. R (1999) The interventional normalization ratio during concurrent warfarin and argatroban anticoagulation differential contributions of each agent and effects of the choice of the thromboplastin used. Clin. Chem. 45(13), 409–412.PubMedGoogle Scholar
  56. 56.
    Lewis, B. E., Leya, F. S., Wallis, D., and Grassman, E. (1994) Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can. J. Cardiol. 10(5), 559.PubMedGoogle Scholar
  57. 57.
    Chamberlin, J. R., Lewis, B., Leya, F., et al. (1995) Successful treatment of heparin-associated thrombocytopenia and thrombosis using hirulog. Can. J. Cardiol. 11(6), 511.PubMedGoogle Scholar
  58. 57a.
    Reid, T., Alving, B. M. (1994) Hrulog therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am. J. Hematol. 45, 352–353.PubMedCrossRefGoogle Scholar
  59. 57b.
    Campbell, K. R., Mahaffey, K. W., Lewis, B. E., Weitz, J. I., Berkowitz, S. D., Ohman, E. M., et al. (2000) Bivalirudin in patients with heparin-induced thrombocytopenia underoing percutaneous coronary intervention. J. Invas. Cardiol. 12(Suppl F), 14F-9.Google Scholar
  60. 58.
    Walenga, J. M., Lewis, B. E., Jeske, W. R., Leya, F., Wallis, D. E., Bakhos, M., et al. (1999) Combined thrombin and platelet inhibition treatment for HIT patients. Hämostaseologie 19, 128–133. Describes the use of the combination of a GP Ilb/IIIa inhibitor and a direct thrombin inhibitor for the treatment of acute thrombosis in patients with HIT.Google Scholar
  61. 59.
    Lewis, B. E., Wallis, D. E., Berkowitz, S. D., Matthai, W. H., Fareed, J., Walenga, J. M., et al., for the ARG-911 Study Investigators (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103(14), 1838–1843. Argatroban is shown to reduce all-cause death, all-cause amputation, and new thrombosis in patients with HIT.PubMedGoogle Scholar
  62. 60.
    Lewis, B. E., Ferguson, J. J., Grassman, E. D., Fareed, J., Walenga, J. M., Joffrion, J. L., et al. (1996) Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J. Invas. Cardiol. 8(9), 410–417.Google Scholar
  63. 61.
    Lewis, B. E., Iqbal, O., Hoppensteadt, D., Ahsan, A., Ahmad, S., Messmore, H. L., et al. (1997) Clinical pharmacokinetic and pharmacodynamic studies on argatroban to optimize the anticoagulant dosage in interventional cardiovascular procedures [abstract]. Thromb. Haemostasis (Suppl.), 492.Google Scholar
  64. 62.
    Lewis, B. E., Rangel, Y., and Fareed, J. (1998) The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome: A case report. Angiology 49(1), 61–67.PubMedCrossRefGoogle Scholar
  65. 63.
    Lewis, B. E., Cohen, M., Moses, J., Matthai, W., for the ARG-216/310/311 investigators (2000) Argatroban anticoagulation during initial and repeat percutaneous coronary intervention in patients with heparin-induced thrombocytopenia [abstract]. Am. J. Cardiol. 86(Suppl. 8A), 141.Google Scholar
  66. 63a.
    Jang, I. K., Lewis, B. E., Matthai, W. H., and Kleiman, N. S. (2003) Combination of a direct thrombin inhibitor, argatroban, and glycoprotein IIb/IIIa inhibitor is effective and safe in patients undergoing percutaneous coronary intervention. J. Am. Coll. Cardiol. 41(6 Suppl A), 68A.CrossRefGoogle Scholar
  67. 64.
    Greinacher, A., Volpel, H., Janssens, U., Hach-Wunderle, V., Kemkes-Matthes, B., Eichler, P., et al., for the HIT Investigators Group (1999) Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation 99, 73–80. Clinical benefit of r-hirudin treatment in HIT patients is described.PubMedGoogle Scholar
  68. 65.
    Greinacher, A., Janssens, U., Berg, G., Bock, M., Kwasny, H., Kemkes-Matthes, B., et al., for the HAT investigators (1999) Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100(6), 587–593.PubMedGoogle Scholar
  69. 66.
    Pötzsch, B. and Klovekorn, W. P. (2000) Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N. Engl. J. Med. 343, 515.PubMedCrossRefGoogle Scholar
  70. 67.
    Koster, A., Loebe, M., Mertzluftt, F., Kuppe, H., and Hetzer, R. (2000) Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant. Ann. Thorac. Surg. 70(6), 2160–2161.PubMedCrossRefGoogle Scholar
  71. 68.
    Kappa, J. R., Fisher, C. A., and Todd, B. (1990) Intraoperative management of patients with heparin-induced thrombocytopenia. Ann. Thorac. Surg. 49, 714.PubMedCrossRefGoogle Scholar
  72. 69.
    Fabrizio, M. C. (2001) Use of the ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J. Extracorp. Tech. 33(2), 117–125.Google Scholar
  73. 70.
    Riess, F. C., Kormann, J., and Poetzsch, B. (2000) Recombinant hirudin as anticoagulant during cardiopulmonary bypass. Anesthesiology 93(6), 1551–1552.PubMedCrossRefGoogle Scholar
  74. 71.
    Shah, A. C.,, Genoni, M., Niederhauser, U., Maloigne, M., and Turina, M. (2000) R-hirudin (lepirudin, refludan) as an alternative anticoagulant in heparin-induced thrombocytopenia during cardiopulmonary bypass connection (German). Schweizerische Medizinische Wocenschrift. Journal Suisse de Medicine 130(23), 896–899.Google Scholar
  75. 72.
    Rubens, F. D., Sabloff, M., Wells, P. S., and Bourke, M. (2000) Use of recombinant hirudin in pulmonary thromboendarterectomy. Ann. Thorac. Surg. 69(6), 1942–1943.PubMedCrossRefGoogle Scholar
  76. 73.
    Koster, A., Loebe, M., Hansen, R., Bauer, M., Mertzlufft, F., Kuppe, H., et al. (2000) A quick assay for monitoring hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: adaptation of the ecarin clotting time to the ACT II device. J. Thorac. Cardiovasc. Surg. 119(6), 1278–1283.PubMedCrossRefGoogle Scholar
  77. 74.
    Longrois, D., de Maistre, E., Bischoff, N., Dopff, C., Meistelman, C., Angioi, M., et al. (2000) Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can. J. Anaesthesiol. 47(3), 255–260.CrossRefGoogle Scholar
  78. 75.
    Latham, P., Revelis, A. F., Joshi, G. R, DiMaio, J. M., and Jessen, M. E. (2000) Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology 92(1), 263–266.PubMedCrossRefGoogle Scholar
  79. 76.
    Koster, A., Pasic, M., Bauer, M., Kuppe, H., and Hetzer, R. (2000) Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function. Ann. Thorac. Surg. 69(1), 37–41.PubMedCrossRefGoogle Scholar
  80. 77.
    Koster, A., Kuppe, H., Hetzer, R., Sodian, R., Crystal, G. J., and Mertzlufft, F. (1998) Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 89(3), 777–780.PubMedCrossRefGoogle Scholar
  81. 77a.
    Lewis, B. E., Grassman, E. D., Wrona, L., Rangel, Y. (1997) Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coag. Fibrinol. 8(1), 54–58.CrossRefGoogle Scholar
  82. 77b.
    Lewis, B. E., Rangel, Y., Fareed, J. (1998) The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Angiology 49, 61–67.PubMedCrossRefGoogle Scholar
  83. 77c.
    Matsuo, T., Chikahira, Y., Yamada, T., Nakao, K., Ueshima, S., Matsuo, O., (1998) Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin-induced thrombocytopenia during hemodialysis. Thromb. Res. 52, 165–171.CrossRefGoogle Scholar
  84. 77d.
    Koide, M., Yamamoto, S., Matsuo, M., Suzuki, S., Arima, N., Matsuo, T., (1995) Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol. Dial. Transplant 10, 2137–2140.PubMedGoogle Scholar
  85. 77e.
    Steuer, S., Boogen, C., Plum, J., Deppe, C., Reinauer, H., Grabensee, B. (1999) Anticoagulation with r-hirudin in a patient with acute renal failure and heparin-induced thrombocytopenia. Nephrol. Dial. Transplant 14, 45–47.PubMedCrossRefGoogle Scholar
  86. 77f.
    Schneider, T., Heuer, B., Deller, A., Boesken, W. H. (2000) Continuous hemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin-induced thrombocytopenia (HIT II). Wein. Klin. Wochenschr. 112, 552–555.Google Scholar
  87. 77g.
    Van Wyck, V., Badenhorst, P. N., Luus, H. G., Kotze, H. F. (1995) A comparison betweenthe use of recombinant hirudin and heparin during hemodialysis. Kidney Int. 48, 1338–1343.CrossRefGoogle Scholar
  88. 77h.
    Manfredi, J. A., Wall, R. P., Sane, D. C., Braden, G. A. (2001) Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports. Cath. Cardiovasc. Intervent. 52(4), 468–472.CrossRefGoogle Scholar
  89. 77i.
    Pinto, D. S., Sperling, R. T., Tu, T. M., Cohen, D. J., Carrozza, J. P. (2003) Combination platelet glycoprotein Ilb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cath. Cardiovasc. Intervent. 58(1), 65–68.CrossRefGoogle Scholar
  90. 78.
    Chong, B. H., Ismail, F., Cade, J., et al. (1989) Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 73(6), 1592.PubMedGoogle Scholar
  91. 79.
    Haas, S., Walenga, J. M., Jeske, W. P., and Fareed, J. (1999) Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. Clin. Appl. Thrombosis/Hemostasis 5(Suppl. 1), 52–59.Google Scholar
  92. 80.
    Magnani, H. N. (1993) Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb. Haemostasis 70(4), 554.Google Scholar
  93. 81.
    Ortel, T. L., Gocherman, J. P., Califf, R. M., et al. (1992) Parenteral anticoagulation with the heparinoid Lomoparan (ORG 10172) in patients with heparin-induced thrombocytopenia and thrombosis. Thromb. Haemostasis 67(3), 292.Google Scholar
  94. 82.
    Cohen, J. I., Cooper, M. R., and Greenberg, C. S. (1985) Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch. Intern. Med. 135, 1725–1726.CrossRefGoogle Scholar
  95. 83.
    Fiessinger, J. N., Aiach, M., Roncato, M., et al. (1984) Critical ischemia during heparin-induced thrombocytopenia. Treatment by intra-arterial streptokinase. Thromb. Res. 33, 235.PubMedCrossRefGoogle Scholar
  96. 84.
    Rao, R. C., Lewis, B. E., and Johnson, S. A. (1995) Thrombolytic experience for treatment of thrombosis in patients with post-operative heparin-induced thrombocytopenia. Blood 86(10)(Suppl. 1), 551a.Google Scholar
  97. 85.
    Haas, S., Walenga, J. M., Jeske, W. P., and Fareed, J. (1999) Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin. Thromb. Hemost. 25(Suppl. 1), 67–76.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Walter P. Jeske
    • 1
  • Jeanine M. Walenga
    • 1
  1. 1.Departments of Thoracic-Cardiovascular Surgery and Pathology, Cardiovascular InstituteLoyola University Medical CenterMaywood

Personalised recommendations